logo
Plus   Neg
Share
Email

Myriad Reports Approval For BRACAnalysis Diagnostic System In Japan

Myriad Genetic Laboratories, Inc., a subsidiary of Myriad Genetics, Inc. (MYGN), announced the Japanese Ministry of Health, Labour, and Welfare has granted manufacturing and marketing approval for the company's BRACAnalysis Diagnostic System to be used as a companion diagnostic with the PARP inhibitor, Lynparza.

Lynparza is marketed by AstraZeneca and Merck. AstraZeneca and Merck are seeking approval of Lynparza in Japan for treating patients with BRCA-mutated metastatic breast cancer.

Gary King, executive vice president of International Operations, said: "As the only approved test in Japan, we will collaborate with our commercial partners to ensure patients with metastatic breast cancer have broad access to BRACAnalysis and Lynparza, once it is approved."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lord & Taylor joined the growing list of U.S. retailers who filed for bankruptcy amid the coronavirus pandemic. Lord & Taylor, one of the oldest department store chains in the U.S., filed for bankruptcy protection in the Eastern Court of Virginia on Sunday. The company operated 38 stores that have remained temporarily closed since March this year due to the pandemic. Thomson International Inc. is recalling Red, Yellow, White, and Sweet Yellow Onions for potential contamination with Salmonella, according to a statement by the U.S. Food and Drug Administration or FDA. The onions are in distribution since May 1, 2020. They were sold to wholesalers, restaurants, and retail stores in all 50 U.S. states, the District of Columbia and Canada. Tyson Foods, Inc. (TSN) reported third quarter adjusted net income per share attributable to company of $1.40 compared to $1.47, a year ago. On average, 12 analysts polled by Thomson Reuters expected the company to report profit per share of $0.94, for the quarter. Analysts' estimates typically exclude...
Follow RTT